QNZ

QNZ (EVP4593) shows strong inhibitory effects on NF-κB transcriptional activation and TNF-α production with IC50s of 11 and 7 nM, respectively. QNZ (EVP4593) is a neuroprotective inhibitor of SOC channel.

Product Specifications

CAS Number

[545380-34-5]

Product Name Alternative

EVP4593

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

NF-κB; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/QNZ.html

Purity

99.50

Solubility

DMSO : ≥ 37 mg/mL

Smiles

NC1=CC2=C(NCCC3=CC=C(OC4=CC=CC=C4)C=C3)N=CN=C2C=C1

Molecular Formula

C22H20N4O

Molecular Weight

356.42

Precautions

H302, H315, H319, H335

References & Citations

[1]Tobe M, et al. Discovery of quinazolines as a novel structural class of potent inhibitors of NF-kappa B activation.|[2]Nekrasov ED, et al. Manifestation of Huntington's disease pathology in human induced pluripotent stem cell-derived neurons. Mol Neurodegener. 2016 Apr 14;11:27.|[3]Wu J, et al. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model. J Neurosci. 2016 Jan 6;36 (1) :125-41.